Mode
Text Size
Log in / Sign up

Adenosine and other interventions show variable success in adult paroxysmal supraventricular tachycardia patientsWhy Your Heart Palpitations Might Be Different

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider individualized strategies for patients with structural heart disease or significant comorbidities.

This retrospective observational study assessed treatment responses in 427 adult patients with paroxysmal supraventricular tachycardia at King Hamad University Hospital in Bahrain. The analysis included pharmacologic and non-pharmacologic interventions such as adenosine, vagal maneuvers, cardioversion, and electrical cardioversion. Symptom presentation data indicated that palpitations were the most common symptom reported in this cohort.

Regarding adenosine efficacy, 80.8% of patients (177 of 219) achieved cardioversion with the first dose. Success rates decreased with additional doses, with 11.4% (25 of 219) responding to a second dose and 7.8% (17 of 219) responding to a third dose. Electrical cardioversion was required in 4.2% of the total population (18 of 427), while pacemaker implantation was documented in 0.7% (3 of 427) for co-existing conduction disease.

Subgroup analyses suggested that patients with structural heart disease and diabetes mellitus experienced reduced success with vagal maneuvers. Conversely, hypertension was associated with a favorable response. Patients with heart failure or ischemic heart disease demonstrated poor response across all management modalities. The study noted that sex-based and age-related response differences were descriptive and require multivariable validation. Kaplan–Meier analyses for the cardioversion subgroup (n = 18) were presented as exploratory and descriptive only. Safety data, including adverse events and tolerability, were not reported.

Imagine feeling your heart suddenly race like a drum in your chest. It starts fast and stops just as quickly. This is a common experience for many people. But what if the reason behind it depends on your health history?

New research from Bahrain offers fresh insights into this condition. It shows that not every heart beat problem is the same. Your body's other health issues play a huge role in how it responds to treatment.

The Surprising Shift

Palpitations are the main sign. Nearly 95% of patients feel them. Most people think this is just a minor annoyance. But for some, it signals a deeper issue.

Doctors used to treat everyone the same way. They gave the same medicine or tried the same tricks. But here is the twist: some patients do not respond well to these standard methods.

Think of your heart's electrical system like a busy highway. Sometimes, a wrong turn sends cars speeding in the wrong lane. This causes the rapid heartbeat.

Doctors try to stop this wrong turn. They use medicine called adenosine. It acts like a temporary traffic light. It forces the heart to reset.

But there is a catch. If your heart has structural damage or diabetes, the traffic light does not work as well. The road is too damaged for the signal to clear the jam.

Researchers looked at 427 patients over six years. They checked their records carefully. They wanted to know what made treatments work or fail.

The results were clear. Adenosine worked for most people. About 81% of patients felt their heart slow down after the first dose. This is a very good sign.

However, the story changes for those with other diseases. Patients with heart failure or blocked arteries did not respond well. Even vagal maneuvers, like bearing down or splashing cold water on the face, were less effective for them.

This doesn't mean this treatment is available yet.

The study also looked at age and gender. Women made up more than half of the group. Their average age was around 53. These differences were noted, but scientists need more data to prove if they are real causes.

If you feel your heart racing, do not panic. Most cases are manageable. The good news is that first-line treatments usually work very well.

But you should talk to your doctor about your full health history. If you have high blood pressure, diabetes, or heart disease, your treatment plan might need to be different.

Do not assume the standard advice fits you perfectly. Your unique health profile matters. A doctor can help you choose the right path.

The Limitations

This study has some limits. It looked back at old records. This means it could not track every detail perfectly. Also, the group was from one hospital in Bahrain. Results might differ in other places.

Scientists call this a "retrospective" study. It is a good start, but it is not the final word. We need more research to confirm these findings everywhere.

What happens next? Researchers will likely run new trials. They will test these ideas on more people. They want to find the best way to help everyone.

Approval for new methods takes time. Safety comes first. Doctors must prove a treatment works for many people before it becomes standard care.

For now, the message is simple. Pay attention to your symptoms. Share your full health story with your doctor. Together, you can manage your heart health better.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectivesThis study aimed to evaluate the clinical characteristics, symptom presentation, and management outcomes of patients diagnosed with paroxysmal supraventricular tachycardia (PSVT) at King Hamad University Hospital (KHUH), a tertiary care center. It examined the influence of demographics, comorbidities, and sex on treatment responses to pharmacologic and non-pharmacologic interventions, including cardioversion.MethodsA retrospective observational study was conducted on 427 adult patients with PSVT (ICD-10: I47.1, confirmed by chart review) between January 2018 and early 2024. Data were extracted from the KHUH HOPE electronic medical records system. Descriptive statistics summarized baseline characteristics; chi-square tests examined categorical associations. Kaplan–Meier analyses for the cardioversion subgroup (n = 18) are presented as exploratory and descriptive only.ResultsFemales comprised 56.9% of the cohort (mean age 52.8 ± 15.2 years). Palpitations were the most common symptom (94.4%). Of 219 patients who received adenosine, 177 (80.8%) achieved cardioversion with the first dose, 25 (11.4%) with the second, and 17 (7.8%) with the third. Vagal maneuvers showed reduced success in patients with structural heart disease and diabetes mellitus. Electrical cardioversion was required in 18 patients (4.2%). Pacemaker implantation was documented in 3 patients (0.7%) for co-existing conduction disease, not as a PSVT treatment. Comorbidities significantly influenced outcomes: hypertension was associated with favorable vagal maneuver response, while heart failure and ischemic heart disease correlated with poor response across all modalities.ConclusionPSVT generally responds well to first-line treatments. However, individualized strategies are warranted for patients with structural heart disease or significant comorbidities. Observed sex-based and age-related response differences are descriptive and require multivariable validation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.